Cargando…

Indeterminate Dendritic Cell Tumor With Persistent Complete Metabolic Response to BRAF/MEK Inhibition

Detalles Bibliográficos
Autores principales:	Thurner, Lorenz, Bewarder, Moritz, Rosar, Florian, Orth, Patrick, Meuter, Raoul Boris, Rixecker, Torben, Lesan, Vadim, Kohn, Dieter Michael, Schneider, Günther, Baumhoer, Daniel, Bohle, Rainer Maria, Veith, Christian, Bittenbring, Joerg Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732267/ https://www.ncbi.nlm.nih.gov/pubmed/33324955 http://dx.doi.org/10.1097/HS9.0000000000000511

Ejemplares similares

Vitamin D Enhances Immune Effector Pathways of NK Cells Thus Providing a Mechanistic Explanation for the Increased Effectiveness of Therapeutic Monoclonal Antibodies
por: Christofyllakis, Konstantinos, et al.
Publicado: (2023)

Increased B‐cell activity with consumption of activated monocytes in severe COVID‐19 patients
por: Kos, Igor, et al.
Publicado: (2021)

Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP
por: Bewarder, Moritz, et al.
Publicado: (2023)

Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells
por: Kiefer, Maximilian, et al.
Publicado: (2022)

Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019
por: Lesan, Vadim, et al.
Publicado: (2021)

Adjuvant Therapy of High-Risk (Stages IIC–IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis
por: Christofyllakis, Konstantinos, et al.
Publicado: (2021)

The riddle of lymphoma BCR-antigenes
por: Thurner, Lorenz, et al.
Publicado: (2018)

Advances in Lymphoma Molecular Diagnostics
por: Kos, Igor Age, et al.
Publicado: (2021)

Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential
por: Bewarder, Moritz, et al.
Publicado: (2020)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Autoantibodies against SUMO1-DHX35 in long-COVID
por: Thurner, Lorenz, et al.
Publicado: (2022)

The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells
por: Bewarder, Moritz, et al.
Publicado: (2021)

IgG seroprevalence of COVID‐19 among people living with HIV or at high risk of HIV in south‐west Germany: A seroprevalence study
por: Kaddu‐Mulindwa, Dominic, et al.
Publicado: (2021)

BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
por: Campos, Maira P., et al.
Publicado: (2018)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
por: Garutti, Mattia, et al.
Publicado: (2022)

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
por: Del Curatolo, Anais, et al.
Publicado: (2018)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules
por: Rowe, Leslie R, et al.
Publicado: (2006)

BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma
por: Migliorini, Denis, et al.
Publicado: (2017)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

Tracking and blocking interdependencies of cellular BRAF-MEK oncokinase activities
por: Fleischmann, Jakob, et al.
Publicado: (2023)

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2
por: Chen, Wenjing, et al.
Publicado: (2023)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
por: Turner, Elizabeth, et al.
Publicado: (2022)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy
por: Estep, Anne L., et al.
Publicado: (2007)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

Role of Specific B-Cell Receptor Antigens in Lymphomagenesis
por: Thurner, Lorenz, et al.
Publicado: (2020)

Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy
por: Mazor, Roei D, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hti7ugo0084bnh91mcbuenu86p